financetom
Business
financetom
/
Business
/
Deere's quarterly profit falls as US tariffs hit farm equipment margins
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deere's quarterly profit falls as US tariffs hit farm equipment margins
Aug 14, 2025 3:55 AM

(Reuters) -Farm-equipment maker Deere & Co ( DE ) reported a lower third-quarter profit and tightened its annual profit forecast on Thursday, pressured by headwinds from U.S. tariffs and muted demand.

Shares of the world's largest farm-equipment maker fell about 4.5% in premarket trading.

U.S. President Donald Trump's sweeping tariffs have impacted companies across sectors, with the manufacturing and industrial firms taking the biggest hit.

Global companies that reported between July 16 and August 8 have projected a combined financial hit of $13.6 billion to $15.2 billion for the full year, a Reuters' global tariff tracker shows.

Trump has said the tariffs are a response to persistent U.S. trade imbalances and declining manufacturing power, and that the moves will bring jobs and investment to the nation.

Deere has also been affected by declining crop prices for wheat, corn and soybeans that are near multi-year lows in North America, which has dented demand for farming equipment.

Farmer have also been gravitating toward renting machinery to cut their costs, which has hit sales of big-ticket equipment such as tractors and combines.

Deere expects its annual profit to be between $4.75 billion and $5.25 billion, compared with its prior estimate of $4.75 billion to $5.50 billion.

"By proactively managing inventory, we've matched production to retail demand," said Deere CEO John May.

Peer CNH Industrial ( CNH ) topped second-quarter earnings estimates earlier this month, but warned that its annual sales could drop below last year's levels.

Both Deere and CNH have struggled to keep up with the steep tractor demand seen in 2022, when farm income hit a record high and pandemic assistance payments gave farmers extra money to upgrade their fleets.

Deere's net income in the third quarter came in at $1.29 billion, or $4.75 per share, compared with $1.73 billion, or $6.29 per share, a year earlier.

Overall, quarterly sales fell about 9% to $12.02 billion from a year ago.

(Reporting by Nathan Gomes in Bengaluru; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CIBC Launching Its First European Canadian Depositary Receipts
CIBC Launching Its First European Canadian Depositary Receipts
Jan 27, 2025
08:13 AM EST, 01/27/2025 (MT Newswires) -- CIBC (CM.TO, CM) on Monday announced the expansion of its Canadian Depositary Receipts platform with the addition of five new 'European CDRs', to be listed on Cboe Canada and available for trading on January 31, 2025, subject to final approval by the Exchange. A statement noted CIBC's first European CDRs are based on...
QXO goes hostile in bid to buy Beacon Roofing for $11 billion
QXO goes hostile in bid to buy Beacon Roofing for $11 billion
Jan 27, 2025
Jan 27 (Reuters) - QXO on Monday took its $11 billion takeover offer to Beacon Roofing's shareholders after the building-products distributor rebuffed its overtures. Beacon's shares were trading at $118.56 before the bell, below the offer price of $124.25 per share, while QXO's stock was marginally higher. The development comes after Beacon earlier this month rejected a $11 billion takeover...
Veru's Enobosarm Meets Primary Endpoint of Preserving Lean Body Mass in Phase 2b Study
Veru's Enobosarm Meets Primary Endpoint of Preserving Lean Body Mass in Phase 2b Study
Jan 27, 2025
08:15 AM EST, 01/27/2025 (MT Newswires) -- Veru ( VERU ) said Monday that a phase 2b clinical trial of enobosarm for overweight and obese patients receiving Wegovy met its primary endpoint of preserving lean body mass in 16 weeks. In the study, overweight and obese patients, over 60 years old, receiving Wegovy showed a 71% reduction in lean body...
Allakos to Discontinue Development of Urticaria Treatment, Cut Staff; Shares Fall
Allakos to Discontinue Development of Urticaria Treatment, Cut Staff; Shares Fall
Jan 27, 2025
08:08 AM EST, 01/27/2025 (MT Newswires) -- Allakos ( ALLK ) said Monday that its phase 1 trial of AK006 in chronic spontaneous urticaria failed to demonstrate therapeutic efficacy and its development will be terminated immediately. The company said it plans to cut its workforce by 75% and retain a small team to explore strategic options and ensure regulatory compliance....
Copyright 2023-2026 - www.financetom.com All Rights Reserved